ProfileGDS5678 / 1427590_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 57% 55% 55% 57% 54% 58% 55% 55% 54% 54% 54% 54% 56% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4976657
GSM967853U87-EV human glioblastoma xenograft - Control 23.3586455
GSM967854U87-EV human glioblastoma xenograft - Control 33.3743555
GSM967855U87-EV human glioblastoma xenograft - Control 43.3880857
GSM967856U87-EV human glioblastoma xenograft - Control 53.2955654
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5703858
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.467555
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3861555
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3112354
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.331254
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3435154
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3174754
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4224656
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3662855